

Class A: ETAGX | Class C: ETCGX | Class I: ETILX | Class N: ETGLX


The Eventide Gilead Fund is a diversified mutual fund that seeks to provide long-term capital appreciation. The fund primarily invests in equity securities of companies that we believe demonstrate values and business practices that are ethical, sustainable, and provide an attractive investment opportunity. The fund also invests in securities that have significant near-term appreciation potential.

TOP HOLDINGS*

XPO Logistics Inc (4.17%) Global provider of transportation and logistics solutions	SunOpta Inc (2.90%) A leading global organic food company
Macquarie Infrastructure Corp (4.03%) Aircraft services, liquid storage and marine terminals	Steel Dynamics Inc (2.48%) Diversified carbon-steel producer and metals recycler
Bluebird Bio Inc (3.44%) Gene therapy and cancer immunotherapy for hematology and oncology	WABCO Holdings Inc (2.38%) Improving commercial vehicle safety, efficiency and connectivity
Lowe's Cos Inc (3.20%) 2,365 home improvement stores in the U.S., Canada and Mexico	Lam Research Corp (2.34%) Supplying wafer fabrication equipment for the semiconductor industry
Wayfair Inc (3.17%) Online sales of furniture and home decor	AbbVie Inc (2.27%) Innovation-driven global biopharmaceuticals

Growth of \$10,000^{† ‡}

Jul 2008–Jun 2017



Percent Returns by Year^{† ‡}

	2009	2010	2011	2012	2013	2014	2015	2016
■ Eventide Gilead Fund	46.08	18.46	0.25	18.15	52.93	17.86	-2.15	0.90
■ S&P 500 Total Return Index**	26.46	15.06	2.11	16.00	32.39	13.69	1.38	11.96
■ Russell Midcap Growth Index**	46.29	26.38	-1.65	15.81	35.74	11.90	-0.20	7.33

Fund Returns[‡]

30 Jun 2017

	YTD	1-year	3-year ^{††}	5-year ^{††}	Since Inception ^{††}
<i>Eventide Gilead Fund</i>					
Class N	16.33%	28.27%	7.09%	17.57%	14.28%
Class A without load	16.30%	28.17%	7.03%	17.51%	17.27%
Class A with 5.75% load	9.61%	20.82%	4.94%	16.44%	16.37%
Class C	15.86%	27.24%	6.24%	16.62%	16.37%
Class I	16.41%	28.51%	7.31%	17.81%	15.45%
<i>Benchmarks</i>					
S&P 500 Total Return Index**	9.34%	17.90%	9.61%	14.63%	9.79%
Russell Mid-Cap Growth Index**	11.40%	17.05%	7.83%	14.19%	10.00%

* Based on percentage of net assets. Holdings can change at any time and should not be considered investment advice.

† These charts compare the Eventide Gilead Fund Class N's performance to index performance over the periods shown. Performance will differ for other fund classes, based upon fees and commissions. The Growth of \$10,000 Chart assumes Class N's inception date of 8 July 2008 for the indices.

‡ The returns shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or on the redemption of Fund shares. Because of ongoing market volatility, Fund performance may be subject to substantial short-term changes.

** The S&P 500 is an index created by Standard & Poor's of American stocks with the largest market capitalization. It is not an investment product available for purchase. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment. It includes mid-cap companies with higher price-to-book ratios and forecasted growth. The volatility of the indices may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as the indices listed.

†† Performance figures for periods greater than 1 year are annualized. The Fund's share classes have different inception dates. Class N has an inception date of 8 July 2008. Class A and Class C have an inception date of 28 October 2009. Class I has an inception date of 2 February 2010. The indices assume an inception date of 8 July 2008.

Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index and unmanaged index returns do not reflect any fees, expenses or sales charges. To obtain the most recent month-end performance information and a current Eventide Gilead Fund prospectus please call the fund, toll free at 1-877-771-EVEN (3836).


Class A: ETAGX | Class C: ETCGX | Class I: ETILX | Class N: ETGLX

OVERVIEW

Fund	Nasdaq	Maximum Sales Charge	12b-1 Fees	Total Expenses	Inception Date
Class A	ETAGX	Front-end*: 5.75%	0.25%	1.48%	10/28/2009
Class C	ETCGX	None	1.00%	2.23%	10/28/2009
Class I	ETILX	None	0.00%	1.23%	2/2/2010
Class N	ETGLX	None	0.20%	1.43%	7/8/2008


Minimum Investment: \$1,000 or \$100 with AIP (Class A, C, N), \$100,000 (Class I)
 Net assets: \$1.37 billion

Portfolio Composition[†]



Equity market capitalization: \$15.4B average, \$3.6B median

Sector Allocation[‡]



Market Risk**

	Std. Dev.	Beta	Alpha	R-Squared
3 Year (Annualized)	16.95%	1.35	-4.71%	68.37%
5 Year (Annualized)	15.23%	1.17	0.83%	54.28%
Inception (Annualized) ^{††}	19.37%	1.04	4.25%	68.26%

MANAGERS

Dr. Finny Kuruvilla has a unique background in healthcare, statistics, and investing. He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master's degree in Electrical Engineering and Computer Science from MIT, and a bachelor's degree from Caltech in Chemistry. He completed his residency and fellowship at the Brigham & Women's Hospital and Children's Hospital Boston where he cared for adult and pediatric patients suffering from a variety of hematologic, oncologic, and autoimmune disorders. Subsequently, he was a research fellow at MIT where he designed and implemented statistical algorithms involving logistic regression and pseudo-Bayesian expectation maximization. As an avid proponent of values-based investing, Dr. Kuruvilla has developed standards for selecting ethical companies at the outset of the stock selection process.



David Barksdale has a background in software development, engineering and management and is primarily responsible for quantitative research, risk analysis and asset allocation. He holds a bachelor's degree from Caltech in Engineering & Applied Science. By developing and applying novel analytical tools and strategies, Mr. Barksdale works to optimize portfolio returns on a risk-adjusted basis.



* Class A is also subject to a maximum deferred sales charge of 1.00%. This and other expenses that apply to a continued investment in the Fund are described in the Fund's prospectus.

† Companies valued at greater than \$10 billion are Large Cap; those at less than \$1 billion are Small Cap. Portfolio Composition is subject to change at any time, and should not be considered investment advice.

‡ The Fund may not invest 25% or more of its total assets in a particular industry or group of industries. A sector is normally composed of many industry groups. Sector Allocation is subject to change at any time, and should not be considered investment advice.

** Source: Zephyr StyleADVISOR, with Fund returns supplied to Zephyr by Morningstar, Inc.

Standard deviation of return measures the average deviations of a return series from its mean. StyleADVISOR calculates standard deviation as the square root of the squared differences of each monthly return from the mean monthly return over the specified period. Beta is a measure of systematic risk, or the sensitivity of ETGLX to movements in the S&P 500 Index (Index). StyleADVISOR defines Beta as the covariance of ETGLX and Index divided by the variance of the Index. Alpha is the mean of the excess return of ETGLX over beta times the Index. The R-Squared (R²) of ETGLX versus the Index is a measure of how closely related the variance of ETGLX returns and the variance of the Index returns are. StyleADVISOR calculates R² by squaring the correlation of monthly returns between ETGLX and the Index over the specified period.

†† Annualized since inception market risk details assume inception date of 1 August 2008 and not Class N's actual inception date of 8 July 2008, as only full month data is included in the market risk calculations.

Mutual Funds involve risk including the possible loss of principal.

Past performance does not guarantee future results. The Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and normally have a lower trading volume than larger companies. The Fund's ethical values screening criteria could cause it to under perform similar funds that do not have such screening criteria. The Fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. Companies in the technology industries have different risks including but not limited to products becoming obsolete, and entrance of competing products. Companies in the Industrial Sector carry various risks including, but not limited to, risk related to debt loads and intense competition. The Fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The Fund can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks. Because of ongoing market volatility, Fund performance may be subject to substantial short-term changes.

Investors should consider the Fund's objectives, risks, charges and expenses carefully before investing or sending money. This and other important information about the Eventide Gilead Fund can be found in the fund's prospectus, which can be obtained at www.eventidefunds.com or by calling 877-771-EVEN (3836). Please read the prospectus carefully before investing. The Fund is distributed by Northern Lights Distributors, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.